• 목록
• 글쓰기

• 페이스북
• 트위터
• 구글+

【39.rpa216.top】

프라그마틱 슬롯 추천 ㄾ 84.rpa216.top ㄾ 오리지날게임

사이트추천 ㄾ 44.rpa216.top ㄾ 무료충전릴게임

바다이야기앱 ㄾ 89.rpa216.top ㄾ 중고게임기매매

모바일릴게임사이트 ㄾ 77.rpa216.top ㄾ 황금성릴게임

바로가기 go !! 바로가기 go !!

슬롯나라 슬롯머신추천 한국파친코 바다이야기기계가격 프라그마틱 무료게임 바다이야기 기계 가격 알라딘체험머니 슬롯게시판 최신릴게임 일본빠찡꼬 강원랜드 슬롯머신 종류 릴박스 오락실게임 우주전함야마토2199 카지노 잭팟 황금성게임정보 무료 야마토 게임 최신 인터넷게임 오리지널 바다이야기 야마토 무료 게임 온라인룰렛 사이다쿨게임 sp야마토 야마토게임 기 릴게임 손오공 바다이야기 pc 버전 인터넷오션게임 사다리게임주소 오션파라다이스예시 손오공게임온라인 신천지게임 하는방법 바다이야기릴게임 바다 이야기 다운 야마토3게임 다운로드 하기 슬롯머신 이기는 방법 로드할 릴게임 사이트 도메인 무료충전릴게임 바다이야기오리지널 황금성사이트 알라딘바로가기 바다이야기 무료게임 바다이야기5 릴게임정글북 온라인 릴게임 정보 게임몰릴게임 파칭코사이트 오션파라다이스 먹튀 슬롯버프 777 잭팟 바다이야기먹튀돈받기 골드몽 알라딘게임공략법 슬롯 추천 디시 릴게임골드몽 바다이야기 2화 릴게임매장 백경게임하는곳주소 황금성포커게임 야마토3다운로드게임사이트 야마토2 릴게임 고전릴게임 온라인황금성주소 바다이야기게임하는방법 손오공 게임 다운 온라인릴게임먹튀검증 황금성릴게임 바다이야기게임기 바다이야기 무료 릴게임먹튀검증 알슬롯 슬롯머신 하는법 바다시즌7게임 야마토 2 다운로드 오션파라 다이스예시 우주 전함 야마토 2205 실시간릴게임사이트 바다이야기백경 슬롯무료체험 온라인 슬롯 공략 무료슬롯 얌얌 야마토게임2 파칭코슬롯 다빈치 다빈치 온라인릴게임예시 알라딘예시 야마토온라인주소 오션슬롯먹튀 슬롯 잘 터지는 바다이야기시즌7 바다신2영상 릴게임 백경 바다이야기부활 온라인 릴게임 손오공 빠징코 슬롯머신 야마토게임 하기 바다이야기 프로그램 야마토 동영상 황금성 사이트 88오락실릴게임 야마토게임공략법 릴게임종류 릴게임환전 백경게임하는곳주소 온라인야마토주소 무료인터넷바다이야기 파칭코게임다운로드 우주전함야마토2199 릴게임먹튀검증 방법 릴게임뜻 실시간바둑이 손오공릴게임예시 야마토2게임하기 안전 검증 릴게임 체리마스터 다운로드 바다이야기 도박 야마토2게임하기 바다이야기꽁머니환전 야마토동영상 바다이야기 게임 방법 PC 슬롯 머신 게임 야마토게임후기 강원랜드 슬롯머신 잭팟 성인오락게임 This article was released as Pharm Edaily Premium Content on October 16, 2025, at 8:07 AM.


[Kim Jiwan, Edaily Reporter] Korea’s biotech sector is on the rise with a string of breakthroughs and investor optimism.
Qurient’s shares jumped nearly 16% on expectations surrounding its next-generation anticancer technology, the dual payload ADC platform designed 소상공인지원 to overcome drug resistance in tumors.
Samsung Biologics also posted strong gains amid expectations of robust third-quarter earnings driven by full-scale operation of its Plant 4 and milesto 기업은행주택담보 ne payments from its subsidiary Samsung Bioepis.
Meanwhile, Vigencell drew attention ahead of its upcoming presentation at ESMO 2025 in Berlin, where its new brain tumor therapy reportedly a 신종플루유급휴가 chieved 90% tumor cell death within just four hours in preclinical tests.
Qurient’s Dual ADC “Targeting Cancer Resistance”
Qurient’s stock soared on growing enthusiasm for its nov 저축은행무직자신용대출 el cancer treatment platform.
According to KG Zeroin’s MP Doctor data on Oct. 15, Qurient closed at \211,50, up \3,090 (15.95%) from the previous day. Analysts say its dual payload antibody- 자동차매매계약 drug conjugate (ADC) technology could become a next-generation anticancer platform.



Kiyoun Nam, CEO of Qurient, at the company’s headquarters in Pangyo on January 21 (Photo=Edaily, reporter Na Eun-kyung)


ADC therapy combines an antibody with a powerful cytotoxic drug, delivering it directly to tumor cells while minimizing harm to healthy tissue. Qurient is developing a dual payload ADC that incorporates its proprietary CDK7 inhibitor (Q901) to reduce drug resistance and extend therapeutic durability.
Recently, the company signed a licensing deal with Synaffix, a subsidiary of the global biomanufacturing giant Lonza, to adopt its Exatecan-based payload and linker technologies. These allow the drug to be released precisely within cancer cells, improving potency and safety.
Kim A-young, an analyst at Daishin Securities, said:“By integrating Synaffix’s technology, Qurient will complete a CDK7 inhibitor-based dual payload ADC platform. This approach could overcome the resistance problems seen in single-payload ADCs and enhance treatment efficacy.”
She added that with Lonza’s production and technical support, development speed and quality will improve, paving the way for faster tech transfer and commercialization.
Seo Geun-hee, an analyst at Samsung Securities, noted:“Qurient’s CDK7 inhibitor Q901 could be the key to resolving ADC resistance, as it may block the DNA replication mechanisms that drive tumor adaptation.”Qurient is currently conducting preclinical studies on QP101, a HER2-targeting dual payload ADC that combines Q901 with a Topo I inhibitor.
Kim added, “QP101 has shown a better balance between efficacy and safety, and related data are expected to be presented at an upcoming conference in the fourth quarter.”
Samsung Biologics, Strong Earnings Outlook
Samsung Biologics surged more than 9% during trading on Oct. 15, closing at \1,127,000, after briefly touching \1,131,000 intraday.
Analysts attributed the rally to favorable foreign exchange rates, full operation of Plant 4, and milestone revenue from Samsung Bioepis.



Samsung Biologics booth at “Bio Japan 2025” (Photo = Samsung Biologics)


Heo Hye-min of Kiwoom Securities forecast that operating profit for Q3 would reach \646.2 billion, up 91% year-on-year and about 28% above market consensus, citing “a favorable exchange rate, milestone inflows, and leverage from full utilization of Plant 4.”
Lee Hee-young of Daishin Securities added that Q3 sales and operating profit were projected at \1.64 trillion and \598.2 billion, up 38% and 77% year-on-year respectively.
“With additional contract wins, visibility for Plant 6 construction, and U.S. expansion plans, Samsung Biologics’ valuation could rise further,” she said.
Lee Ji-soo of Daol Investment & Securities also noted, “Earnings are expected to exceed market expectations in Q3 and remain strong in Q4 thanks to Plant 4’s full operation. After the planned spin-off, the company’s management structure will stabilize, and global production strategies, including potential U.S. facilities, will become clearer.”
Samsung Biologics is set to finalize its spin-off of CDMO and new drug development divisions on Oct. 17. The market anticipates new announcements on Plant 6 construction and U.S. expansion plans thereafter.
With the recent U.S. BioSecure Act amendment under the National Defense Authorization Act (NDAA), analysts say the company could benefit from a surge in domestic biomanufacturing demand in the U.S.
Vigencell’s Brain Tumor Breakthrough?
Vigencell announced that it will unveil preclinical results for its brain tumor therapy candidate VC302 at ESMO 2025, one of the world’s largest oncology congresses, held in Berlin from Oct. 17 to 21.
The company’s stock closed 8.56% (\285) higher at \3,615, buoyed by investor expectations ahead of the presentation.



The study, conducted jointly with Professor Ji-hoon Phi’s pediatric neurosurgery team at Seoul National University Hospital, tested the anticancer efficacy of GD2 CAR-iNK cells. natural killer (NK) cells engineered with GD2-targeted chimeric antigen receptors (CARs).
In both 3D spheroid tumor models and glioblastoma mouse models, GD2 CAR-iNK cells demonstrated remarkable tumor-killing ability. Within just four hours, more than 90% of tumor cells were destroyed, while untreated control groups showed no change.
In mice, tumor signals almost disappeared within 150 days, and no notable side effects or weight changes were observed.
Vigencell CEO Ki Pyung-seok stated:“Glioblastoma is a difficult-to-treat tumor with strong stem-cell-like resistance to chemotherapy. This study confirmed that GD2 CAR-NK cell therapy can selectively target and remove these resistant cells. We aim to accelerate the development and clinical entry of VC302, with the goal of global technology transfer in the near future.”
김지완 (2pac@edaily.co.kr)

추천0